The overarching goal of our research is the development of prognostic imaging signatures defining biomarkers of disease progression and response to therapy. Methods are developed in pre-clinical studies and translated to human clinical applications.
Due to the diversity of tissue characteristics and responses to therapy, there is a vital need to define disease beyond the traditional staging of location, size, and spread. We believe a better understanding of pathophysiology, protein and gene expression can guide optimized individualized therapy.
Our goals are to integrate state-of-the-art instrumentation and applications to facilitate technique development based on physics, chemistry, and molecular biology.
Our methods focus on MRI, but with additional integrated applications of optical, radionuclide and photoacoustic imaging.